3rd Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Education about the value of innovative new medicines. S. 1878: "To extend the pediatric priority review voucher program". S. 3056: CREATES Act of 2016.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3056 (114th), S. 1878 (114th)

Medicare/Medicaid MMM

H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models. Educated staff about access to therapies for rare diseases in Medicaid. Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals. March 2016 CMS proposed rule implementing a new Part B drug payment model.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5122 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.